Breast Cancer - Pipeline Review, H1 2016


#774429

3011pages

Global Markets Direct

$ 2500

In Stock

Breast Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Breast Cancer - Pipeline Review, H1 2016, provides an overview of the Breast Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Breast Cancer
- The report reviews pipeline therapeutics for Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Breast Cancer therapeutics and enlists all their major and minor projects
- The report assesses Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Breast Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Breast Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 15
Breast Cancer Overview 16
Therapeutics Development 17
Breast Cancer - Therapeutics under Development by Companies 19
Breast Cancer - Therapeutics under Investigation by Universities/Institutes 59
Breast Cancer - Pipeline Products Glance 68
Breast Cancer - Products under Development by Companies 72
Breast Cancer - Products under Investigation by Universities/Institutes 134
Breast Cancer - Companies Involved in Therapeutics Development 148
Breast Cancer - Therapeutics Assessment 582
Drug Profiles 693
Breast Cancer - Dormant Projects 2810
Breast Cancer - Discontinued Products 2869
Breast Cancer - Product Development Milestones 2881
Appendix 2893

List of Tables
Number of Products under Development for Breast Cancer, H1 2016 134
Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2016 135
Number of Products under Development by Companies, H1 2016 137
Number of Products under Development by Companies, H1 2016 (Contd..1) 138
Number of Products under Development by Companies, H1 2016 (Contd..2) 139
Number of Products under Development by Companies, H1 2016 (Contd..3) 140
Number of Products under Development by Companies, H1 2016 (Contd..4) 141
Number of Products under Development by Companies, H1 2016 (Contd..5) 142
Number of Products under Development by Companies, H1 2016 (Contd..6) 143
Number of Products under Development by Companies, H1 2016 (Contd..7) 144
Number of Products under Development by Companies, H1 2016 (Contd..8) 145
Number of Products under Development by Companies, H1 2016 (Contd..9) 146
Number of Products under Development by Companies, H1 2016 (Contd..10) 147
Number of Products under Development by Companies, H1 2016 (Contd..11) 148
Number of Products under Development by Companies, H1 2016 (Contd..12) 149
Number of Products under Development by Companies, H1 2016 (Contd..13) 150
Number of Products under Development by Companies, H1 2016 (Contd..14) 151
Number of Products under Development by Companies, H1 2016 (Contd..15) 152
Number of Products under Development by Companies, H1 2016 (Contd..16) 153
Number of Products under Development by Companies, H1 2016 (Contd..17) 154
Number of Products under Development by Companies, H1 2016 (Contd..18) 155
Number of Products under Development by Companies, H1 2016 (Contd..19) 156
Number of Products under Development by Companies, H1 2016 (Contd..20) 157
Number of Products under Development by Companies, H1 2016 (Contd..21) 158
Number of Products under Development by Companies, H1 2016 (Contd..22) 159
Number of Products under Development by Companies, H1 2016 (Contd..23) 160
Number of Products under Development by Companies, H1 2016 (Contd..24) 161
Number of Products under Development by Companies, H1 2016 (Contd..25) 162
Number of Products under Development by Companies, H1 2016 (Contd..26) 163
Number of Products under Development by Companies, H1 2016 (Contd..27) 164
Number of Products under Development by Companies, H1 2016 (Contd..28) 165
Number of Products under Development by Companies, H1 2016 (Contd..29) 166
Number of Products under Development by Companies, H1 2016 (Contd..30) 167
Number of Products under Development by Companies, H1 2016 (Contd..31) 168
Number of Products under Development by Companies, H1 2016 (Contd..32) 169
Number of Products under Development by Companies, H1 2016 (Contd..33) 170
Number of Products under Development by Companies, H1 2016 (Contd..34) 171
Number of Products under Development by Companies, H1 2016 (Contd..35) 172
Number of Products under Development by Companies, H1 2016 (Contd..36) 173
Number of Products under Development by Companies, H1 2016 (Contd..37) 174
Number of Products under Development by Companies, H1 2016 (Contd..38) 175
Number of Products under Investigation by Universities/Institutes, H1 2016 176
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 177
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 178
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 179
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 180
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 181
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..6) 182
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..7) 183
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..8) 184
Comparative Analysis by Late Stage Development, H1 2016 185
Comparative Analysis by Clinical Stage Development, H1 2016 186
Comparative Analysis by Early Stage Development, H1 2016 187
Comparative Analysis by Unknown Stage Development, H1 2016 188
Products under Development by Companies, H1 2016 189
Products under Development by Companies, H1 2016 (Contd..1) 190
Products under Development by Companies, H1 2016 (Contd..2) 191
Products under Development by Companies, H1 2016 (Contd..3) 192
Products under Development by Companies, H1 2016 (Contd..4) 193
Products under Development by Companies, H1 2016 (Contd..5) 194
Products under Development by Companies, H1 2016 (Contd..6) 195
Products under Development by Companies, H1 2016 (Contd..7) 196
Products under Development by Companies, H1 2016 (Contd..8) 197
Products under Development by Companies, H1 2016 (Contd..9) 198
Products under Development by Companies, H1 2016 (Contd..10) 199
Products under Development by Companies, H1 2016 (Contd..11) 200
Products under Development by Companies, H1 2016 (Contd..12) 201
Products under Development by Companies, H1 2016 (Contd..13) 202
Products under Development by Companies, H1 2016 (Contd..14) 203
Products under Development by Companies, H1 2016 (Contd..15) 204
Products under Development by Companies, H1 2016 (Contd..16) 205
Products under Development by Companies, H1 2016 (Contd..17) 206
Products under Development by Companies, H1 2016 (Contd..18) 207
Products under Development by Companies, H1 2016 (Contd..19) 208
Products under Development by Companies, H1 2016 (Contd..20) 209
Products under Development by Companies, H1 2016 (Contd..21) 210
Products under Development by Companies, H1 2016 (Contd..22) 211
Products under Development by Companies, H1 2016 (Contd..23) 212
Products under Development by Companies, H1 2016 (Contd..24) 213
Products under Development by Companies, H1 2016 (Contd..25) 214
Products under Development by Companies, H1 2016 (Contd..26) 215
Products under Development by Companies, H1 2016 (Contd..27) 216
Products under Development by Companies, H1 2016 (Contd..28) 217
Products under Development by Companies, H1 2016 (Contd..29) 218
Products under Development by Companies, H1 2016 (Contd..30) 219
Products under Development by Companies, H1 2016 (Contd..31) 220
Products under Development by Companies, H1 2016 (Contd..32) 221
Products under Development by Companies, H1 2016 (Contd..33) 222
Products under Development by Companies, H1 2016 (Contd..34) 223
Products under Development by Companies, H1 2016 (Contd..35) 224
Products under Development by Companies, H1 2016 (Contd..36) 225
Products under Development by Companies, H1 2016 (Contd..37) 226
Products under Development by Companies, H1 2016 (Contd..38) 227
Products under Development by Companies, H1 2016 (Contd..39) 228
Products under Development by Companies, H1 2016 (Contd..40) 229
Products under Development by Companies, H1 2016 (Contd..41) 230
Products under Development by Companies, H1 2016 (Contd..42) 231
Products under Development by Companies, H1 2016 (Contd..43) 232
Products under Development by Companies, H1 2016 (Contd..44) 233
Products under Development by Companies, H1 2016 (Contd..45) 234
Products under Development by Companies, H1 2016 (Contd..46) 235
Products under Development by Companies, H1 2016 (Contd..47) 236
Products under Development by Companies, H1 2016 (Contd..48) 237
Products under Development by Companies, H1 2016 (Contd..49) 238
Products under Development by Companies, H1 2016 (Contd..50) 239
Products under Development by Companies, H1 2016 (Contd..51) 240
Products under Development by Companies, H1 2016 (Contd..52) 241
Products under Development by Companies, H1 2016 (Contd..53) 242
Products under Development by Companies, H1 2016 (Contd..54) 243
Products under Development by Companies, H1 2016 (Contd..55) 244
Products under Development by Companies, H1 2016 (Contd..56) 245
Products under Development by Companies, H1 2016 (Contd..57) 246
Products under Development by Companies, H1 2016 (Contd..58) 247
Products under Development by Companies, H1 2016 (Contd..59) 248
Products under Development by Companies, H1 2016 (Contd..60) 249
Products under Development by Companies, H1 2016 (Contd..61) 250
Products under Investigation by Universities/Institutes, H1 2016 251
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 252
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 253
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 254
Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 255
Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 256
Products under Investigation by Universities/Institutes, H1 2016 (Contd..6) 257
Products under Investigation by Universities/Institutes, H1 2016 (Contd..7) 258
Products under Investigation by Universities/Institutes, H1 2016 (Contd..8) 259
Products under Investigation by Universities/Institutes, H1 2016 (Contd..9) 260
Products under Investigation by Universities/Institutes, H1 2016 (Contd..10) 261
Products under Investigation by Universities/Institutes, H1 2016 (Contd..11) 262
Products under Investigation by Universities/Institutes, H1 2016 (Contd..12) 263
Products under Investigation by Universities/Institutes, H1 2016 (Contd..13) 264
Breast Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016 265
Breast Cancer - Pipeline by 4SC AG, H1 2016 266
Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H1 2016 267
Breast Cancer - Pipeline by AB Science SA, H1 2016 268
Breast Cancer - Pipeline by AbbVie Inc., H1 2016 269
Breast Cancer - Pipeline by AbGenomics International, Inc., H1 2016 270
Breast Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016 271
Breast Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016 272
Breast Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 273
Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 274
Breast Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 275
Breast Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016 276
Breast Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016 277
Breast Cancer - Pipeline by Aduro BioTech, Inc., H1 2016 278
Breast Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016 279
Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2016 280
Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2016 281
Breast Cancer - Pipeline by Advaxis, Inc., H1 2016 282
Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 283
Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H1 2016 284
Breast Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016 285
Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H1 2016 286
Breast Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016 287
Breast Cancer - Pipeline by Affichem SA, H1 2016 288
Breast Cancer - Pipeline by Agenus, Inc., H1 2016 289
Breast Cancer - Pipeline by Agilvax, Inc., H1 2016 290
Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2016 291
Breast Cancer - Pipeline by Alchemia Limited, H1 2016 292
Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2016 293
Breast Cancer - Pipeline by Almac Discovery Limited, H1 2016 294
Breast Cancer - Pipeline by Alteogen Inc., H1 2016 295
Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2016 296
Breast Cancer - Pipeline by Ambrx, Inc., H1 2016 297
Breast Cancer - Pipeline by American Gene Technologies International Inc., H1 2016 298
Breast Cancer - Pipeline by Amgen Inc., H1 2016 299
Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 300
Breast Cancer - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016 301
Breast Cancer - Pipeline by Angion Biomedica Corp., H1 2016 302
Breast Cancer - Pipeline by ANP Technologies, Inc., H1 2016 303
Breast Cancer - Pipeline by AntiCancer, Inc., H1 2016 304
Breast Cancer - Pipeline by Antigen Express, Inc., H1 2016 305
Breast Cancer - Pipeline by Antoxis Limited, H1 2016 306
Breast Cancer - Pipeline by Aphios Corporation, H1 2016 307
Breast Cancer - Pipeline by APIM Therapeutics AS, H1 2016 308

List of Figures
Number of Products under Development for Breast Cancer, H1 2016 134
Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2016 135
Number of Products under Development by Companies, H1 2016 136
Number of Products under Investigation by Universities/Institutes, H1 2016 176
Comparative Analysis by Late Stage Development, H1 2016 185
Comparative Analysis by Clinical Stage Development, H1 2016 186
Comparative Analysis by Early Stage Products, H1 2016 187
Assessment by Monotherapy Products, H1 2016 699
Assessment by Combination Products, H1 2016 700
Number of Products by Top 10 Targets, H1 2016 701
Number of Products by Stage and Top 10 Targets, H1 2016 701
Number of Products by Top 10 Mechanism of Actions, H1 2016 752
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 752
Number of Products by Top 10 Routes of Administration, H1 2016 806
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 806
Number of Products by Top 10 Molecule Types, H1 2016 808
Number of Products by Stage and Top 10 Molecule Types, H1 2016 808